Apheresis for the treatment of relapses in MS and NMOSD: reduced antibody reactivities, gene expression changes and potential clinical response indicators

Apheresis for the treatment of relapses in MS and NMOSD: reduced antibody reactivities, gene expression changes and potential clinical response indicators

BackgroundHigh-dose glucocorticoids are the standard treatment for acute relapses in patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD). Therapeutic apheresis can be considered for the escalation of relapse therapy, but some patients still do not recover sufficie...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael Hecker, Brit Fitzner, Isis Ludwig-Portugall, Friederike Bohne, Edmar Heyland, Juliane Klehmet, Matthias Grothe, Matthias Schwab, Alexander Winkelmann, Stefanie Meister, Ales Dudesek, Hannah Wurm, Ilya Ayzenberg, Ingo Kleiter, Corinna Trebst, Martin W. Hümmert, Bernhard Neumann, Klaus Eulitz, Dirk Koczan, Uwe K. Zettl
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Immunology
Subjects:
multiple sclerosis
neuromyelitis optica spectrum disorder
acute relapse
apheresis
glucocorticoids
antibodies
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1531447/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1531447/full

Similar Items